Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers July 22, 2017
Pharmacy Choice - News - Pharmaceutical Development - July 22, 2017

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

6/22/17 - Alembic Pharmaceuticals gets USFDA nod for Amantadine Hydrochloride Capsules [India Infoline News Service]
Alembic Pharmaceuticals on Thursday announced that it has received approval from the US Food& Drug Administration for its Abbreviated New Drug Application for Amantadine Hydrochloride Capsules, USP, 100 mg. Alembic Pharmaceuticals on Thursday announced that it has received approval from the US Food& Drug Administration for its Abbreviated New Drug.
6/22/17 - Alzheon to Present Novel Molecular Mechanism of Action and Long Term Clinical Efficacy Data for Lead Candidate ALZ-801 at the Alzheimer's Association International Conference
Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer s disease and other neurological and psychiatric disorders, today announced that the company will be making three presentations at the Alzheimer s Association International Conference to be held in London on July
6/22/17 - Ampio Injects First Patient in Final Pivotal Clinical Trial for Ampion? BLA
Ampio Pharmaceuticals, Inc. initiates dosing in the AP-003-C, Phase 3, single injection Ampion? study. The study's primary endpoint follows the Outcome Measures in Rheumatology Clinical Trials and Osteoarthritis Research Society International guidance, utilizing the OMERACT-OARSI responder rate....
6/22/17 - Anatomic Pathology Market is likely to reach approx. USD 22 billion till 2022
It is expected to reach approximately USD 22 billion by the end of 2022.. Key players profiled in the report are Abbott Diagnostics, Agilent Technologies, Danaher, Roche Diagnostics, Thermo Fisher Scientific, Abcam, AdnaGen, Advanced Cell Diagnostics, Agendia, Angsana Molecular& Diagnostics Laboratory, AutoGenomics, Biocare Medical, Biocartis, Cell
6/22/17 - Annual ASCO Meeting Suggests an Optimistic Future for Cancer Care
The University of Michigan's Comprehensive Cancer Center issued the following news release:. About 39,300 cancer professionals from around the world met June 2-6 in Chicago for the American Society of Clinical Oncology Annual Meeting. Daniel F. Hayes, M.D., co-director of the Breast Oncology Program at the University of Michigan Comprehensive Cance
6/22/17 - Ascendis Pharma Adopts New Global Communications Model With Fuze
Fuze, the leading cloud-based communications solution provider for the modern global enterprise, has been selected by Ascendis Pharma to create a modern communications infrastructure that will support the rapidly growing biotech firm in its collaboration with multiple research partners, manufacturers, and clinical trial specialists worldwide.
6/22/17 - Biohaven Broadens Senior Leadership Team With Veteran Pharma Executives
NEW HAVEN, Conn., June 22, 2017/ PRNewswire/- Biohaven Pharmaceutical Holding Company Ltd. and it's wholly owned subsidiary, Biohaven Pharmaceuticals, Inc., today announced recent key additions to its senior leadership team as it develops an expanded portfolio of therapeutic candidates across multiple neurological disorders. Dr. Stock has more th
6/22/17 - Bionext Launches Biosight: an Online Platform That Will Revolutionize Pharmaceutical Research [ITWeb]
Bionext, a bioinformatics company, announces today the launch of BioSight, an online bio-simulation platform designed for efficient identification of possible side effects of potential drug treatments on the human body. 3.975 billion dollars per drug That is the average total cost of R&D needed for pharmaceutical companies to launch a new drug on t
6/22/17 - BioPharmX to Present Phase 2b Clinical Trial Acne Data at Alabama Dermatology Society Summer Symposium
BioPharmX Corporation, a specialty pharmaceutical company focusing on dermatology, will present results of its phase 2 b of BPX-01, a unique topical hydrophilic gel formulation of minocycline, at the Alabama Dermatology Society's Summer Symposium being held June 22-25 in Sandestin, Fla.. James Q. Del Rosso, founder of JDR Dermatology Research, La
6/22/17 - Cara Therapeutics Reports Continuation of Phase 3 Trial of I.V. CR845 in Postoperative Pain Following Interim Assessment [Sudan Tribune]
-Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced the completion of a prespecified interim conditional power analysis of its adaptive Phase 3 trial of I.V.
6/22/17 - Cara Therapeutics` Phase 3 Trial Will Continue, Studies Postoperative Pain Treatment [Sport360]
Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, announced the completion of a prespecified interim conditional power analysis of its adaptive Phase 3 trial of I.V.
6/22/17 - Chi-Med Initiates a Phase I/II Clinical Trial of Novel FGFR Inhibitor HMPL-453 in China
Hutchison China MediTech Limited has just initiated a Phase I/II clinical trial of HMPL-453 in China. The first drug dose was administered on June 19, 2017. This study complements the first-in-human Phase I clinical trial in Australia that was initiated earlier this year.
6/22/17 - Clinical Trials: Past, Present and Future Survey Report Released by SCORR Marketing and Applied Clinical Trials
SCORR Marketing, a global health science marketing and communications firm, has announced that a new survey report, Clinical Trials: Past, Present and Future is now available for free download. Clinical trials have changed dramatically in the last decade, said Cliff Echols, market intelligence director at SCORR Marketing. More than ever, s
6/22/17 - Credence Research: Brisk Insights Identifies Key Growth Opportunities In The Contract Research Organization (CRO) Services Market
According to the recent report published by Brisk Insights, the Global Contract Research Organization Services Market is expected to provide sustainable growth opportunities during the forecast period from 2017 to 2025. Full report available: Global Contract Research Organization Services market forecast 2017-2025 report at...
6/22/17 - CTD Holdings Enrolls First Patient in European Phase I/II Clinical Trial of Trappsol(R) Cyclo(TM) for Treatment of Niemann-Pick Disease Type C [Syrian Arab News Agency]
CTD Holdings, Inc., a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced that it has enrolled the first patient in the Company`s European Phase I/II clinical trial evaluating the intravenous administration of Trappsol Cyclo in patients with Niemann-Pick Disease Type C, a rare
6/22/17 - DelMar Pharmaceuticals Receives Institutional Review Board Approval for Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM
DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of new cancer therapies, today announced it has received Institutional Review Board approval to conduct its pivotal Phase 3 Study in Temozolomide-Avastin Recurrent GBM. IRB approval is an essential step in initiating patient enrollment in our Phase 3 trial, s
6/22/17 - DURECT Completes Enrollment in PERSIST, Phase 3 trial for POSIMIR
DURECT Corporation today announced that patient enrollment has been completed in PERSIST, the pivotal Phase 3 clinical trial of POSIMIR , an investigational locally acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery. In May 2017, DURECT signed a development and commercialization agreement w
6/22/17 - Enrollment in Phase 1/2a Study of IONIS-HTT Rx in Patients with Huntington's Disease Completed and Open-Label Extension Study to Open in 2H 2017
Ionis Pharmaceuticals, Inc. today announced the completion of enrollment in the Phase 1/ 2 a randomized, placebo-controlled, dose escalation study of IONIS-HTT Rx in patients with Huntington's disease. Dosing in the final patient cohort continues, and Ionis plans to report top-line results from this study around year-end 2017. Upon completion and
6/22/17 - FDA accepts application for generic version of Advair Diskus
The FDA has accepted Sandoz's New Drug Application for fluticasone propionate / salmeterol combination product, a generic version of Advair Diskus...
6/22/17 - FDA approves new Shire drug for ADHD [T-break Tech (Middle East)]
Federal regulators Tuesday approved a new drug developed by Shire plc to treat attention deficit hyperactivity disorder in patients 13 years and older. Shire, a leading maker of rare disease medicines, said it plans to make the newly approved ADHD drug available for commercial use in the United States in the third quarter. In a safety notice requir
6/22/17 - FDA-approved drugs in combination could provide new antibiotics [T-break Tech (Middle East)]
The team analysed a dataset of 4,000 E.coli mutants that were developed in the presence of 100 FDA- approved drugs. The mutants bacteria each had a specific gene missing and reacted to whichever drug it was grown alongside uniquely. Researchers were then able to produce a dataset with the various chemical genetic signatures produced from the intera
6/22/17 - FibroGen Granted Orphan Drug Designation for Pamrevlumab in the Treatment of Pancreatic Cancer
FibroGen, Inc., a science-based biopharmaceutical company, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation status to pamrevlumab, the company s first-in-class antibody, for the treatment of pancreatic cancer. This is an important regulatory milestone for FibroGen, as pamrevlumab continues to sh
6/22/17 - Findings from Duke University Broaden Understanding of Clinical Trials and Studies (Has the rising placebo response impacted antidepressant clinical...
By a News Reporter-Staff News Editor at Politics& Government Week Investigators discuss new findings in Clinical Research- Clinical Trials and Studies. According to news reporting originating from Durham, North Carolina, by VerticalNews correspondents, research stated, "More than fifteen years ago, it was noted that the failure rate of antidepres
6/22/17 - Gauss Surgical Receives FDA Clearance for Second Generation Triton for Real-Time Monitoring of Surgical Blood Loss
Gauss Surgical, Inc. announced today that the company received U.S. Food and Drug Administration clearance for its second generation Triton OR system, a mobile platform for accurate, real-time estimation of surgical blood loss. Measurement of blood loss is a challenge that has plagued surgical departments for decades. The FDA first cleared the Trit
6/22/17 - GNW-News: Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack (english)
Novartis Phase III study shows ACZ885 reduces cardiovascular risk in people who survived a heart attack. Novartis International AG/ Novartis Phase III study shows ACZ885 reduces cardiovascular risk in people who survived a heart attack. Processed and transmitted by Nasdaq Corporate Solutions.
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415